Effectiveness and Cost-Effectiveness of Expanded Antiviral Prophylaxis and Adjuvanted Vaccination Strategies for an Influenza A (H5N1) Pandemic
- 15 December 2009
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 151 (12) , 840-853
- https://doi.org/10.7326/0000605-200912150-00156
Abstract
No abstract availableThis publication has 73 references indexed in Scilit:
- Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and childrenVaccine, 2008
- Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trialVaccine, 2008
- Quantifying the Routes of Transmission for Pandemic InfluenzaBulletin of Mathematical Biology, 2008
- Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trialThe Lancet, 2007
- H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probesJournal of Virological Methods, 2007
- Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trialThe Lancet, 2006
- Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trialThe Lancet, 2006
- The cost-effectiveness of influenza vaccination of healthy adults 50–64 years of ageVaccine, 2006
- Transmission of infectious diseases during commercial air travelThe Lancet, 2005
- Recommendations of the Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996